ARTICLE | Product Development
BioNTech testing separate mRNA vaccine variant in Chinese trial, closes supply deal with Canada
Plus data for Relief’s peptide, EUA for a saliva test and clinical plans for ImmunityBio’s vaccine
August 6, 2020 1:59 AM UTC
BioNTech started a Chinese COVID-19 vaccine trial Wednesday that will test a different mRNA candidate than the pivotal, global study the biotech is running with Pfizer. Separately, the partners announced a vaccine procurement agreement with Canada.
COVID-19 countermeasure updates also came this week for Relief’s anti-inflammatory peptide and ImmunityBio’s vaccine, plus Clinical Reference Laboratory scored an Emergency Use Authorization (EUA) for its saliva diagnostic...